Updated:
LivaNova PLC
LivaNova PLC, formed in 2015 via Sorin-Cyberonics merger, is a London based medical device firm in cardiac surgery and neuromodulation.
LivaNova PLC
LivaNova PLC formed in 2015 when Italy's Sorin Group merged with US-based Cyberonics in a $2.7 billion all-stock transaction (per Reuters, 2015). The combined entity inherited Sorin's heart-lung machines and Cyberonics' implanted nerve stimulators for epilepsy and depression. Both founding companies trace origins to the 1950s and 1970s respectively, giving LivaNova roughly 70 years of cumulative regulated-device experience. LivaNova's product portfolio splits into two main units: Cardiovascular (heart-lung machines, oxygenators, perfusion systems) and Neuromodulation (VNS Therapy for epilepsy and depression, plus emerging VNS asthma/respiratory applications). The company invests roughly 10% of annual revenue in R&D, with clinical trials for new indications ongoing (per the firm's annual report, 2023). Manufacturing sites span Italy, Germany, the US, and Malaysia, generating sales in over 100 countries. The public company has roughly 3,000 employees globally and trades on the Nasdaq under ticker LIVN. Market capitalization stood at approximately $1.1 billion as of May 2026. In October 2023, the company reorganized into two focused business segments to streamline operational execution (per SEC filing, October 2023). No separate family-office or private-investment arm has been publicly identified. As a publicly traded corporation, LivaNova operates under corporate governance with an elected board and SEC disclosure obligations. Its structural differentiator lies in its dual-market reach: it controls a dominant share of the cardiopulmonary-bypass niche while also being one of only two FDA-approved makers of implanted vagus nerve stimulators for epilepsy. That dual-technology platform creates patent-moat overlap rare among med-tech mid-caps.
General information
Firm type
other
Year founded
2015
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Sector focus
Frequently asked questions
Who makes the investment decisions at LivaNova PLC?
LivaNova is a public company with a board of directors overseeing strategy. Day-to-day operational and capital-allocation decisions are handled by the CEO and executive management team, guided by board-approved plans. The board is elected by shareholders per standard corporate governance.
What is LivaNova's core business model?
LivaNova designs, manufactures, and sells medical devices used in cardiac surgery (heart-lung machines, oxygenators) and neuromodulation (implantable vagus nerve stimulators). It generates revenue through equipment sales, disposable/recurring-use component sales, and service contracts. The company operates across regulated markets with ISO 13485 and FDA compliance.
Does LivaNova have any family-office or private-investment structure?
No. LivaNova PLC is incorporated as a public limited company in England and Wales and trades on the Nasdaq stock exchange. There is no disclosed family-office, private-investment vehicle, or controlling-family wealth-management entity tied to the firm. Its largest shareholders are institutional investors.
Which sectors or technology areas does LivaNova systematically avoid?
LivaNova concentrates exclusively on regulated medical devices for cardiac surgery and neuromodulation. It does not pursue pharmaceutical, diagnostic, digital-health, or consumer-health markets. The company has no disclosed exposure to real estate, venture capital, or alternative investments.
What is LivaNova's known posture on co-investments or external fund commitments?
As a public company, LivaNova does not operate a dedicated internal investment team or engage in co-investment partnerships with external GPs. Capital allocation focuses on organic R&D, selective bolt-on acquisitions, and share repurchases or dividends per board policy. Any external fund activity would appear in SEC filings.
How did the 2015 merger shape LivaNova's current product lineup?
The merger combined Sorin Group's leadership in cardiopulmonary bypass and heart-valve repair with Cyberonics' monopoly-positioned vagus nerve stimulation for epilepsy. This gave the new firm two independently strong, regulated-technology platforms serving different surgical specialties, reducing single-market dependence.
Where does LivaNova's underlying wealth or capital come from?
LivaNova is a publicly traded operating company, not a family office or investment vehicle. Its capital comes from public equity markets, retained earnings, and debt issuance. No private-wealth origin or family fortune is attached to the entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: